Focused On-demand Library for Synaptonemal complex protein 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9BX26

UPID:

SYCP2_HUMAN

Alternative names:

Synaptonemal complex lateral element protein

Alternative UPACC:

Q9BX26; A2RUE5; O75763; Q5JX11; Q9NTX8; Q9UG27

Background:

Synaptonemal complex protein 2, also known as a major component of the axial/lateral elements of synaptonemal complexes (SCS) during meiotic prophase, plays a pivotal role in the assembly of these complexes. It is essential for normal meiotic chromosome synapsis in oocyte and spermatocyte development, ensuring normal male and female fertility. This protein's function is critical for the insertion of SYCP3 into synaptonemal complexes and may also contribute to chromatin organization by binding to DNA scaffold attachment regions.

Therapeutic significance:

Given its crucial role in meiotic chromosome synapsis and fertility, Synaptonemal complex protein 2 is directly linked to Spermatogenic failure 1, a disorder characterized by azoospermia due to spermatogenic arrest. Understanding the role of Synaptonemal complex protein 2 could open doors to potential therapeutic strategies for treating infertility disorders.